Circulating free DNA as a prognostic biomarker in patients with advanced ALK+ NSCLC treated with alectinib from the global phase III ALEX trial.
2019
9053Background:
Circulating free DNA(cfDNA) released predominantly by tumors into the blood correlates with tumor load, but correlation with outcomes after
ALK inhibitortreatment is poorly unders...
Keywords:
-
Correction
-
Source
-
Cite
-
Save
0
References
0
Citations
NaN
KQI